Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and.
Q3 Net loss per share of $0.01 vs. a net loss of $0.18 per share from same period last year InFoods® IBS diagnostic-guided therapy clinical trial results.
Studies show that 13-20% of Canadians suffer from IBS at any given time1. The lifetime risk for a Canadian to develop IBS is 30%1. IRVINE, Calif., Nov. .